Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

624
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
624
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.3K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.3K
Amyloid Fibrils03:03

Amyloid Fibrils

11.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.4K
Amyloid Fibrils03:03

Amyloid Fibrils

6.1K
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Immune cell senescence and chronic bone diseases: osteoimmune mechanisms and therapeutic perspectives.

Frontiers in immunology·2026
Same author

Targeting the cGAS-STING pathway alleviates neuroinflammation and cognitive impairment induced by chronic infection of Toxoplasma gondii.

Journal of neuroinflammation·2026
Same author

Immune cell senescence and chronic bone diseases: osteoimmune mechanisms and therapeutic perspectives.

Frontiers in immunology·2026
Same author

Non-invasive Computational Techniques for Diagnosing Myocardial Ischemia: Challenges and Future of FFR<sub>CT</sub>/iFR<sub>CT</sub>.

Annals of biomedical engineering·2026
Same author

Sulfur-modified iron-based biochar via feature-sparsified cascade transfer learning: from interfacial structure regulation to phosphate adsorption performance optimization.

Bioresource technology·2026
Same author

<i>Staphylococcus argenteus</i> ST2250 from diabetic foot sepsis: genomic insights into resistance and virulence.

Frontiers in cellular and infection microbiology·2026

Related Experiment Video

Updated: Dec 3, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K

Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.

Bin-Lu Sun1,2,3, Yang Chen1,2,3, Dong-Yu Fan1,2,3

  • 1Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, 400042, China.

Science China. Life Sciences
|October 27, 2020
PubMed
Summary

Alzheimer's disease (AD) treatments targeting amyloid-beta (Aβ) have largely failed. A broader approach addressing tau, inflammation, and systemic factors is crucial for effective AD management.

Keywords:
Alzheimer’s diseaseamyloid βenzyme inhibitorimmunotherapymulti-target therapytertiary prevention strategyβ-secretaseγ-secretase

More Related Videos

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.8K
A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.3K

Related Experiment Videos

Last Updated: Dec 3, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K
Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.8K
A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.3K

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Amyloid-beta (Aβ) is a primary target in Alzheimer's disease (AD) research.
  • Despite extensive research, most Aβ-targeted therapies have not succeeded in clinical trials.
  • This highlights the need to re-evaluate current therapeutic strategies for AD.

Purpose of the Study:

  • To analyze challenges and critical points in current anti-Aβ therapeutic strategies.
  • To explore alternative and complementary therapeutic targets beyond Aβ.
  • To emphasize the need for tertiary prevention and systemic approaches in AD management.

Main Methods:

  • Review of current literature on Alzheimer's disease pathogenesis and therapeutic strategies.
  • Analysis of the limitations of amyloid-beta-centric approaches.
  • Identification of synergistic pathological pathways involved in AD progression.

Main Results:

  • Most clinical trials targeting amyloid-beta have failed, indicating limitations of this strategy.
  • Other pathological factors like tau hyperphosphorylation, oxidative stress, and neuroinflammation are critical contributors to AD.
  • A systemic perspective and multidomain interventions are essential for AD treatment.

Conclusions:

  • Rethinking amyloid-beta-targeted strategies is necessary for Alzheimer's disease.
  • Addressing multiple pathological pathways, including tau, oxidative stress, and neuroinflammation, offers promising therapeutic avenues.
  • Tertiary prevention and holistic approaches targeting brain and systemic factors are vital for managing Alzheimer's disease.